47% of the patients in this study had complete response (CR) on all oral regimen of decitabine–cedazuridine 5 days every 28 days plus venetoclax 400mg daily.
After 10 years one third of the heavily pretreated lymphoma patients who had CAR-T therapy stayed disease free.
Progression-free survival was improved in the tafa-len-R-CHOP group vs the R-CHOP with 2-year progression-free survival rates of 71·1vs 62·9% toxicity was higher with tafa-len-R-CHOP with a higher rate of fatal treatment-emergent adverse events, but more overall deaths the RCHOP arm. It is early to add Len taf because of toxicity esp with OS survival and deep response data being immature.
The median overall survival (OS) was 27·9 months with ivonescimab versus 23·7 months with tis.
Median progression-free survival was significantly longer with sac-TMT plus pembrolizumab than with pembrolizumab alone (not reached vs 5·7 m) this is regardless of PDL-1 expression (1-49 or >50).
Progression-free survival (PFS) was statistically significantly improved with addition of tucatinib versus placebo 24.9 v 16.3 months regardless of the presence/absence of BM or hormone receptor status.
This is the first prospective randomized trial demonstrating that ctDNA guided Adjuvant chemotherapy (ACT) improves time to recurrence (TTR) and Disease-free survival (DFS) in stage II colon cancer pts without clinical risk factors, pt with negative CtDNA had better overall survival (OS) and DFS than pts with positive CtDNA, Pts who with Positive CtDNA who and chemotherapy also had better DFS compared to the ones who underwent surveillance (77% vs 38%).
1467 pts with RS > 25 and 551 with clinically (neoadjuvant cohort in ADAPT-HR+/HER2-) or pathologically N2, (longer) docetaxel-based CTx showed better distant, invasive disease-free survival in N2-3 pts patients with RS ≤25, OS was also shown in pts with RS>25 anthracycline regimens did not show a significant survival difference in high-risk HR+/HER2 whether used in neoadjuvant or adjuvant setting. So may be no anthracycline for HR+ve pts who are high risk disease.
Adding olaparib to Radium 223 improve progression-free survival (PFS) in patients with bone mets (median 8.9 v 4.7 month) esp. in those who did not receive prior taxotere.
One or 2 doses pre op then completing a year of therapy lead to pCR in 53% of patients with MSI, the pCR increased from 46% after one dose to 68% after 2 doses.